Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Stuttgart
Clinical trial register · Germany

Clinical Trials in Stuttgart, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2873
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals8 Merck Sharp & Dohme LLC8 University Hospital Tuebingen6 Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)4 Hoffmann-La Roche4
Site location
Berlin1586 Hamburg889 Essen766 Dresden716 Heidelberg627
All 639 locations
Target enrolment
to

Trials with a site in Stuttgart

117 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Chiesi Farmaceutici S.p.A.
Phase 3
700
Frankfurt, Göttingen, Jena, Stuttgart
2026-11-16
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Mainz, Stuttgart
2026-10-19
Not yet open
NutrImmune: Precision Nutrition to Improve Immunity in Individuals With Obesity
NCT07850206Obesity (BMI>30), Immune Abnormalities, Low-grade Inflammation
DrugBiological sampling
Institut National de la Santé Et de la Recherche Médicale, France
Not applicable
168
Stuttgart
2026-10-01
Recruiting
Novartis Pharmaceuticals
Phase 2
180
Stuttgart, Kaiserslautern, Berlin, Mannheim, Pirna
2026-09-18
Recruiting
Boehringer Ingelheim
Phase 3
466
Berlin, Bonn, Essen, Hanover, Heidelberg, München, Stuttgart
2026-09-17
Recruiting
Bristol-Myers Squibb
Phase 2
160
Stuttgart, Marburg, Homburg, Cologne, Haile, Hessen
2026-09-10
Recruiting
Medical University Innsbruck
Phase 2
48
Stuttgart
2026-07-13
Recruiting
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NCT07531927Geographic Atrophy Secondary to Age-related Macular Degeneration
Okuvision GmbH
Not applicable
70
Hamburg, München, Stuttgart, Tübingen, Ulm
2026-05-05
Recruiting
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Not applicable
66
Stuttgart
2026-03-31
Recruiting
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Not applicable
93
Stuttgart
2026-03-04
Recruiting
Maquet Cardiovascular
Observational
200
Rostock, Stuttgart, Wuppertal
2026-03-04
Recruiting
Insmed Incorporated
Phase 3
344
Heidelberg, Immenhausen, Stuttgart, München, Bonn, Essen, Homburg, Dresden
2026-01-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Göppingen, Stuttgart, Tübingen, Ulm, Donauwörth, München, Regensburg, Traunstein
2026-01-02
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
Freiburg im Breisgau, Hamburg, Stuttgart
2025-12-19
Recruiting
University of Cologne
Phase 3
420
Stuttgart, Nuremberg, Aachen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf
2025-12-16
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Dresden, Essen, München, Stuttgart
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Stuttgart, Tübingen, Göttingen, Schwerin, Herne, Münster, Dresden, Erfurt
2025-11-26
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Heidelberg, Stuttgart, Tübingen, Düsseldorf, Herne, Minden, Chemnitz, Jena
2025-11-25
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Pfizer
Phase 2
200
Stuttgart, Münster, Berlin, Dresden, Leipzig, Wuppertal
2025-10-30
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Recruiting
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Not applicable
30
Freiburg im Breisgau, Ludwigsburg, Stuttgart
2025-10-02
Recruiting
Pfizer
Phase 3
680
Heidelberg, Stuttgart, Hösbach, Frankfurt am Main, Giessen, Immenhausen, Kassel, Bonn
2025-09-29
Recruiting
Daiichi Sankyo
Phase 2/3
630
Eisleben Lutherstadt, Herne, Nürtingen, Stuttgart
2025-09-26
Recruiting
BeOne Medicines
Phase 3
500
Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm
2025-09-04
Recruiting
Sanofi
Phase 3
192
Berlin, Essen, Stuttgart
2025-08-12
Recruiting
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Stuttgart, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Lübeck
2025-08-11
Not yet open
Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry
NCT07142902Subepithelial Gastrointestinal Tumors, Adenoma
Ovesco Endoscopy AG
Observational
306
Freiburg im Breisgau, Ludwigsburg, Stuttgart
2025-08
By invitation
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Not applicable
172
Stuttgart, Würzburg
2025-06-05
Recruiting
Penumbra Inc.
Observational
300
Cologne, Leipzig, Stuttgart
2025-05-18
Recruiting
University Hospital Tuebingen
Not applicable
66
Stuttgart
2025-05-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Potsdam, Frankfurt am Main, Cologne, Duisburg
2025-05-13
Recruiting
Biogen
Phase 3
454
Heidelberg, Stuttgart, Villingen-Schwenningen, Frankfurt am Main, Braunschweig, Mainz, Dresden, Leipzig
2025-05-08
Recruiting
SUPRATHEL 250 as a Treatment for Oropharyngeal Wounds
NCT06543823Tonsillitis, Tonsillectomy, Tonsillitis Recurrent
Alaa Emara
Not applicable
80
Stuttgart
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Recruiting
University Hospital, Bonn
Phase 2
176
Freiburg im Breisgau, Stuttgart, Giessen, Minden, Bonn
2025-04-20
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Stuttgart, Tübingen, Ulm, Erlangen, Munich, Würzburg, Frankfurt am Main, Kassel
2025-04-11
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Stuttgart, Munich, Herne, Halle, Jena
2025-03-11
Recruiting
BioTex, Inc.
Not applicable
30
Stuttgart, München, Bonn, Lünen, Leipzig, Mannheim
2025-02-17
Recruiting
Robert Bosch Medical Center
Observational
100
Stuttgart
2025-02-01
Recruiting
Ascentage Pharma Group Inc.
Phase 3
490
Berlin, Dresden, Düsseldorf, Halle, Leipzig, Stuttgart, Ulm
2025-01-22
Recruiting
AIO-Studien-gGmbH
Phase 2
57
Berlin, Dresden, Essen, Flensburg, Frankfurt, Minden, München, Stuttgart
2025-01-01
Recruiting
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
NCT06456359Desmoplastic Small Round Cell Tumor, Synovial Sarcoma
University Hospital Heidelberg
Phase 2
28
Heidelberg, Stuttgart, Essen
2024-12-19
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Greifswald, Leipzig, München, Stuttgart
2024-12-16
Recruiting
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
NCT06201234Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
DrugsElacestrant·Olaparib
GBG Forschungs GmbH
Phase 2
176
Stuttgart, Tübingen, Winnenden, Weinheim, Augsburg, Bayreuth, Fürstenwalde, Frankfurt am Main
2024-12-13
Active, closed
Hoffmann-La Roche
Phase 2
62
Berlin, Heidelberg, Herne, Stuttgart
2024-12-09
Recruiting
OSE Immunotherapeutics
Phase 3
363
Heidelberg, Stuttgart, Gauting, München, Kassel, Aachen, Bonn, Essen
2024-12-03
Recruiting
University Hospital Tuebingen
Not applicable
64
Stuttgart
2024-11-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Heidelberg, Stuttgart, Kempten (Allgäu), Giessen, Oldenburg, Eschweiler, Münster, Mainz
2024-10-21
Recruiting
ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos
NCT06920680Colorectal Cancer, Colonoscopy, Polypectomy
Wuerzburg University Hospital
Observational
1,834
Stuttgart, Würzburg
2024-10-01
Recruiting
Novartis Pharmaceuticals
Observational
500
Konstanz, Stuttgart, Munich, Regensburg, Würzburg, Cottbus, Frankfurt (Oder), Ludwigshafen
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
Bayer
Phase 3
444
Stuttgart, Nuremberg, Frankfurt am Main, Giessen, Cologne, Essen, Hemer, Berlin
2024-08-28
Recruiting
University of Cologne
Phase 2
20
Stuttgart, Freiburg im Breisgau, Cologne, Hamburg, Essen, Berlin
2024-08-23
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart
2024-08-15
Recruiting
University Hospital Tuebingen
Not applicable
120
Stuttgart
2024-07-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Stuttgart, Greifswald, Bielefeld, Solingen
2024-05-24
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
Essen, Leipzig, Stuttgart
2024-04-22
Recruiting
Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
NCT07137260Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, Digital Mobility Outcomes
Simon Jäger
Observational
77
Stuttgart, Munich, Nuremberg, Löwenstein
2024-04-19
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 1/2
112
Berlin, Cologne, Freiburg im Breisgau, Greifswald, Halle, Kiel, Münster, Stuttgart
2024-04-15
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Stuttgart, Munich, Dresden, Jena, Berlin, Hamburg
2024-04-10
Recruiting
Marc Bosiers, MD
Observational
109
Berlin, Frankfurt, Göttingen, Heidelberg, Lünen, Münster, Regensburg, Stuttgart
2024-04-05
Recruiting
Pfizer
Phase 3
492
Freiburg im Breisgau, Stuttgart, Ulm, Nuremberg, Bonn, Berlin, Cottbus, Hamm
2024-02-08
Active, closed
Pfizer
Phase 3
394
Stuttgart, Bad Bentheim, Münster
2024-01-19
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Mutlangen, Stuttgart, Munich, Frankfurt am Main, Essen, Mainz, Halle, Kiel
2023-12-28
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Heidenheim, Konstanz, Mannheim, Schorndorf, Stuttgart, Augsburg, Munich, Bremenhaven
2023-12-20
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Stuttgart, Mutlangen, Frankfurt am Main, Essen, Mainz, Homburg, Dresden, Berlin
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Stuttgart, Würzburg, Mutlangen, Frankfurt am Main, Mainz, Dresden, Berlin, Kiel
2023-12-12
Recruiting
W.L.Gore & Associates
Not applicable
244
Bad Krozingen, Münster, Regensburg, Stuttgart
2023-10-17
Recruiting
The Lymphoma Academic Research Organisation
Phase 3
260
Amberg, Berlin, Kiel, Ludwigshafen, Regensburg, Stuttgart, Trier, Ulm
2023-09-05
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Bad Oeynhausen, Bremen, Hanover, Stuttgart, Tübingen
2023-09-01
Active, closed
Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas
NCT06124690Persistent Atrial Fibrillation, Catheter Ablation, Low Voltage Areas
Robert Bosch Medical Center
Not applicable
150
Stuttgart
2023-09-01
Recruiting
Auricular Acupuncture in Patients With Advanced Cancer: a Randomized Clinical Trial.
NCT05762250Fatigue, Pain, Depression, Advanced Tumour Diseases
University Hospital Tuebingen
Not applicable
125
Stuttgart, Würzburg
2023-08-13
Recruiting
University Hospital Freiburg
Phase 3
340
Freiburg im Breisgau, Stuttgart, Aachen, Augsburg, Berlin, Bielefeld, Bochum, Braunschweig
2023-08-09
Active, closed
Hoffmann-La Roche
Phase 3
459
Leipzig, Aachen, Berlin, Cologne, Hanover, Mainz, Stuttgart, Villingen-Schwenningen
2023-08-08
Active, closed
MED-EL Elektromedizinische Geräte GesmbH
Not applicable
20
Stuttgart, Würzburg, Gera, Berlin
2023-07-27
Recruiting
University Hospital Tuebingen
Not applicable
100
Stuttgart
2023-06-10
Active, closed
Amgen
Phase 3
509
Berlin, Cologne, Dresden, Essen, Gauting, Großhansdorf, Stuttgart, Würzburg
2023-05-31
Recruiting
Varian, a Siemens Healthineers Company
Not applicable
132
Stuttgart, Homburg
2023-04-13
Active, closed
Bayer
Phase 3
985
Mannheim, Nürtingen, Stuttgart, Würzburg, Frankfurt am Main, Braunschweig, Göttingen, Aachen
2023-04-03
Active, closed
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
NCT05397106Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
Integra LifeSciences Corporation
Observational
160
Dortmund, Düsseldorf, Essen, Freiburg im Breisgau, Stuttgart
2023-01-24
Recruiting
Women's Cancer Study Group GmbH
Observational
1,470
Baden-Baden, Pforzheim, Stuttgart, Ulm, Weinheim, Karlsruhe, Ravensburg, Amberg
2022-12-07
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bad Mergentheim, Elsterwerda, Essen, Hamburg, Leipzig, Münster, Stuttgart, Wangen
2022-11-01
Recruiting
TolerogenixX GmbH
Phase 2
126
Berlin, Hamburg, Heidelberg, Munich, Münster, Stuttgart
2022-05-04
Recruiting
Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®
NCT05114850Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure
P+F Products + Features GmbH
Observational
450
Freiburg im Breisgau, Friedrichshafen, Heilbronn, Regensburg, Stuttgart, Winnenden
2022-04-20
Active, closed
AbbVie
Observational
634
Freiburg im Breisgau, Heidelberg, Langenau, Stuttgart, Freising, Memmingen, Munich, Nuremberg
2021-12-13
Active, closed
AbbVie
Observational
338
Baden-Baden, Heidelberg, Stuttgart, Tübingen, Ulm, Hoppegarten, Potsdam, Bruchhausen-Vilsen
2021-11-22
Active, closed
Boehringer Ingelheim
Phase 1
151
Freiburg im Breisgau, Halle, Stuttgart
2021-10-18
Recruiting
University Hospital Tuebingen
Phase 1
46
Bonn, Freiburg im Breisgau, Heidelberg, Heilbronn, Mannheim, München, Stuttgart, Tübingen
2021-10-12
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Heidelberg, Kiel
2021-09-20
Active, closed
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
NCT04931368Primary Central Nervous System Lymphoma
Klinikum Stuttgart
Phase 3
331
Stuttgart
2021-06-28
Recruiting
University Hospital Heidelberg
Not applicable
326
Heidelberg, Marburg, Stuttgart
2021-04-19
Active, closed
Hoffmann-La Roche
Phase 3
746
Berlin, Böblingen, Dresden, Giessen, Kiel, Stuttgart, Tübingen, Ulm
2021-03-17
Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
NCT06601270Spontaneous Coronary Artery Dissection
European Society of Cardiology
Observational
1,500
Bad Rothenfelde, Berlin, Hamburg, Stuttgart
2021-01-30
Active, closed
Prof. Dr. med. Claus Rödel
Phase 3
702
Esslingen am Neckar, Freiburg im Breisgau, Mannheim, Mutlangen, Offenburg, Ostfildern, Stuttgart, Tübingen
2020-11-05
Active, closed
Krankenhaus Nordwest
Phase 3
127
Frankfurt am Main, Göttingen, Leipzig, Stuttgart
2020-07-15
Active, closed
Abbott Medical Devices
Observational
20
Stuttgart, München, Leipzig, Hanover
2019-10-24
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Stuttgart, Cologne, Berlin, Essen
2019-07-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Stuttgart, Tübingen, Erlangen, Munich, Würzburg, Bonn, Dresden, Magdeburg
2019-07-24
Active, closed
IMPEDE and IMPEDE-FX Embolization Plug Registry
NCT04044443Peripheral Vascular Embolization
Shape Memory Medical, Inc.
Observational
108
Dresden, Heidelberg, Kiel, Leipzig, München, Nuremberg, Stuttgart, Würzburg
2019-07-09
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
366
Essen, Frankfurt am Main, Homburg / Saar, Offenburg, Ravensburg, Schwerte, Stuttgart, Torgau
2019-06-14
Active, closed
AbbVie
Phase 3
265
Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg
2018-10-22
Active, closed
Ottawa Heart Institute Research Corporation
Not applicable
176
Leipzig, Stuttgart
2018-09-01
Active, closed
Wuerzburg University Hospital
Phase 3
576
Freiburg im Breisgau, Mutlangen, Ravensburg, Stuttgart, Ulm, Villingen-Schwenningen, Amberg, Augsburg
2018-08-28
Active, closed
Janssen Research & Development, LLC
Phase 3
120
Bonn, Dresden, Frankfurt, Kiel, Langenau, Selters, Stuttgart
2018-07-11
Active, closed
Hoffmann-La Roche
Phase 3
927
Dresden, Greifswald, Stuttgart, Ulm, Westerstede, Wiesbaden
2018-05-28
Recruiting
BioInvent International AB
Phase 1/2
140
Frankfurt am Main, Stuttgart
2018-05-16
Recruiting
AbbVie
Observational
500
Mutlangen, Stuttgart, Villingen-Schwenningen, Aschaffenburg, Augsburg, Bad Reichenhall, Erlangen, Hof
2017-12-04
Recruiting
Universität Duisburg-Essen
Not applicable
94
Stuttgart
2017-09-06
Active, closed
Tetec AG
Observational
42
Mannheim, Stuttgart, München, Regensburg, Kiel
2017-04-25
Active, closed
Universitätsmedizin Mannheim
Phase 3
314
Augsburg, Berlin, Leipzig, Mannheim, Munich, Stuttgart, Wuppertal
2016-12-09
Active, closed
Eisai Inc.
Phase 3
1,069
Stuttgart, Tübingen, München, Frankfurt am Main, Hanover, Greifswald, Münster, Homburg/Saar
2016-10-13
Active, closed
Bayer
Phase 1/2
154
Heidelberg, Stuttgart, Berlin
2015-12-16
Recruiting
Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy
NCT02304913Acupuncture, Taste Disorders, Dysgeusia, Chemotherapy
Universität Duisburg-Essen
Not applicable
75
Essen, Mannheim, Stuttgart
2015-01-01
Active, closed
University of Virginia
Observational
2,750
Berlin, Heidelberg, Stuttgart
2014-04
Recruiting
Technische Universität Dresden
Observational
15,000
Baden-Baden, Heidelberg, Mannheim, Schwäbisch Hall, Sindelfingen, Stuttgart, Winnenden, Augsburg
2010-09
Recruiting
University of Hohenheim
Not applicable
480
Heidelberg, Stuttgart, Tübingen
2009-05
Rows per page Showing 1–117 of 117
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/stuttgart

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 117 of those studies with a site in Stuttgart.

How many clinical trials are recruiting in Stuttgart?

77 of the 117 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 35 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Stuttgart), 117 studies
PhaseStudiesRecruitingShare
Phase 3432436.8%
Not applicable231819.7%
Observational221318.8%
Phase 2181415.4%
Phase 1/2645.1%
Phase 2/3332.6%
Phase 1211.7%

Most active sponsors

Lead sponsors with the most studies (Stuttgart)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC86
Novartis Pharmaceuticals85
University Hospital Tuebingen66
AbbVie41
Hoffmann-La Roche40
Pfizer43
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)43
Bayer31
Boehringer Ingelheim31
Bristol-Myers Squibb33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.